tradingkey.logo

Biofrontera Announces New Patent Protection On Ameluz Until 2043

ReutersMay 15, 2025 6:51 PM

- Biofrontera Inc BFRI.O:

  • BIOFRONTERA INC. ANNOUNCES NEW PATENT PROTECTION ON AMELUZ® UNTIL 2043 AND THE COMPLETION OF PATIENT ENROLLMENT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS

  • BIOFRONTERA INC - EXPECTS LAST-PATIENT-OUT IN Q3 2025 FOR AMELUZ TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI